×
About 3,660 results

ALLMedicine™ Multiple System Atrophy Center

Research & Reviews  1,259 results

Clinical Laboratory Evaluation of Chronic Autonomic Failure
https://clinicaltrials.gov/ct2/show/NCT03648905

Jul 1st, 2022 - Objective: In dysautonomias, altered function of one or more components of the autonomic nervous system adversely affect health. A subset of dysautonomias consists of chronic autonomic failure (CAF) syndromes. A key sign of CAF is orthostatic hypo...

Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease
https://clinicaltrials.gov/ct2/show/NCT03705520

Jun 27th, 2022 - First, a cross sectional study where the investigators will compare microbiome composition in subsets of PD and Multiple System Atrophy (MSA) patients whose household control agree to provide stool samples as well. Each household control subject w...

Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerad...
https://doi.org/10.1016/j.parkreldis.2022.06.008
Parkinsonism & Related Disorders; Carlos AF, Sekiya H et. al.

Jun 26th, 2022 - Multiple system atrophy (MSA) typically presents with parkinsonism, ataxia and/or autonomic dysfunction. Occasionally, clinically atypical (ca-MSA) cases masquerade as progressive supranuclear palsy (PSP). We aimed to investigate whether different...

COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of...
https://doi.org/10.1111/ene.15475
European Journal of Neurology; Kuo MC, Lu YC et. al.

Jun 25th, 2022 - Multiple system atrophy (MSA) has no definitive genetic or environmental (G-E) risk factors, and the integrated effect of these factors on MSA etiology remains unknown. To investigate the integrated effect of G-E factors associated with MSA and it...

Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking...
https://doi.org/10.1136/jnnp-2021-327376
Journal of Neurology, Neurosurgery, and Psychiatry; Lawton M, Tan MM et. al.

Jun 23rd, 2022 - To explore the genetics of four Parkinson's disease (PD) subtypes that have been previously described in two large cohorts of patients with recently diagnosed PD. These subtypes came from a data-driven cluster analysis of phenotypic variables. We ...

see more →

Guidelines  2 results

Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and tr...
https://doi.org/10.1016/j.parkreldis.2021.03.027
Parkinsonism & Related Disorders; Calandra-Buonaura G, Alfonsi E et. al.

Apr 12th, 2021 - Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by a combination of autonomic failure plus cerebellar syndrome and/or parkinsonism. Dysphagia is a frequent and disabling symptom in MSA and its occurrence within 5 years ...

My Treatment Approach to Multiple System Atrophy.
https://doi.org/10.1016/j.mayocp.2020.10.005
Mayo Clinic Proceedings; Coon EA, Ahlskog JE

Mar 7th, 2021 - Multiple system atrophy (MSA) is a neurodegenerative disorder primarily characterized by autonomic failure plus parkinsonism or cerebellar ataxia. The diagnosis may be challenging and is usually made at a tertiary care center. The long-term manage...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  115 results

Clinical Laboratory Evaluation of Chronic Autonomic Failure
https://clinicaltrials.gov/ct2/show/NCT03648905

Jul 1st, 2022 - Objective: In dysautonomias, altered function of one or more components of the autonomic nervous system adversely affect health. A subset of dysautonomias consists of chronic autonomic failure (CAF) syndromes. A key sign of CAF is orthostatic hypo...

Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease
https://clinicaltrials.gov/ct2/show/NCT03705520

Jun 27th, 2022 - First, a cross sectional study where the investigators will compare microbiome composition in subsets of PD and Multiple System Atrophy (MSA) patients whose household control agree to provide stool samples as well. Each household control subject w...

A Study of Lu AF82422 in Participants With Multiple System Atrophy
https://clinicaltrials.gov/ct2/show/NCT05104476

Jun 10th, 2022 - The participants will be randomized to Lu AF82422 or placebo (2:1).

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
https://clinicaltrials.gov/ct2/show/NCT02897063

Jun 9th, 2022 - Patients with multiple system atrophy, pure autonomic failure or Parkinson disease, and orthostatic hypotension will be studied in a randomized, double-blind, 2-arm parallel design to compare the effects of droxidopa and midodrine on stoke volume ...

TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System Atrophy
https://clinicaltrials.gov/ct2/show/NCT04450992

Jun 8th, 2022 - TRACK-MSA is designed to relate phenotypic characteristics of participants with MSA using several modalities (i.e., clinical, quantitative motor, imaging, laboratory) in order to relate phenotypic characteristics with data derived from the study o...

see more →

News  60 results

The First Signs of Elusive Dysautonomia May Appear on the Skin
https://www.medscape.com/viewarticle/955470

Jul 27th, 2021 - The initial manifestations of dysautonomia may be dermatologic related, so awareness of what to look for is essential. During the annual meeting of the Society for Pediatric Dermatology, Adelaide A. Hebert, MD, defined dysautonomia as an umbrella ...

The first signs of elusive dysautonomia may appear on the skin
https://www.mdedge.com/dermatology/article/243306/dermatology/first-signs-elusive-dysautonomia-may-appear-skin
Doug Brunk

Jul 23rd, 2021 - The initial manifestations of dysautonomia may be dermatologic related, so awareness of what to look for is essential. Dr.

Blood biomarker may predict Parkinson’s disease progression
https://www.mdedge.com/neurology/article/228309/parkinsons-disease/blood-biomarker-may-predict-parkinsons-disease
Jim Kling

Sep 10th, 2020 - A novel biomarker could help identify progression in Parkinson’s disease, distinguish it from other neurodegenerative disorders, and monitor response to treatments. Although the biomarker, neurofilament light chain (NfL), is not especially specifi.

BRIEF-Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
https://www.reuters.com/article/brief-biohavens-verdiperstat-receives-fa/brief-biohavens-verdiperstat-receives-fast-track-designation-for-the-treatment-of-multiple-system-atrophy-idUSFWN2BB0DD

Mar 18th, 2020 - March 18 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd: * BIOHAVEN’S VERDIPERSTAT RECEIVES FAST TRACK DESIGNATION FOR THE TREATMENT OF MULTIPLE SYSTEM ATROPHY Source text for Eikon: Further company coverage:

Best timing for measuring orthostatic vital signs?
https://www.mdedge.com/familymedicine/article/211801/cardiology/best-timing-measuring-orthostatic-vital-signs
MDedge Family Medicine; Deborah Phipps, MD, Erik Butler, DO et. al.

Nov 7th, 2019 - ILLUSTRATIVE CASE A 54-year-old woman with a history of hypertension presents with a chief complaint of dizziness. You require an assessment of orthostatic vital signs to proceed.

see more →

Patient Education  9 results see all →